Steroid Sparing in Immune Related Hepatitis (irH)
A Study to Evaluate the Efficacy and Safety of Steroid Sparing Strategy in Immune Related Hepatitis
Sponsor: AHS Cancer Control Alberta
This NA trial investigates Hepatitis Immune and is currently actively recruiting participants. AHS Cancer Control Alberta leads this study, which shows 9 recorded versions since 2025 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2025 — Feb 2026 [monthly]
Not Yet Recruiting NA
-
Sep 2024 — Jun 2025 [monthly]
Not Yet Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting NA
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting NA
▶ Show 4 earlier versions
-
Nov 2023 — Apr 2024 [monthly]
Not Yet Recruiting NA
-
Apr 2023 — Nov 2023 [monthly]
Not Yet Recruiting NA
-
Sep 2022 — Apr 2023 [monthly]
Not Yet Recruiting NA
-
May 2022 — Sep 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AHS Cancer Control Alberta
For direct contact, visit the study record on ClinicalTrials.gov .